Several other equities analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of BeyondSpring from a hold rating to a sell rating in a research note on Monday, November 13th. Maxim Group set a $52.00 price objective on shares of BeyondSpring and gave the stock a buy rating in a research note on Thursday, November 30th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company currently has an average rating of Buy and an average price target of $54.50.
BeyondSpring (NASDAQ BYSI) opened at $31.59 on Monday. BeyondSpring has a 1 year low of $16.55 and a 1 year high of $48.49.
A hedge fund recently bought a new stake in BeyondSpring stock. Tanaka Capital Management Inc. bought a new position in BeyondSpring Inc. (NASDAQ:BYSI) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 21,322 shares of the company’s stock, valued at approximately $914,000. BeyondSpring makes up about 2.1% of Tanaka Capital Management Inc.’s portfolio, making the stock its 16th biggest holding. Tanaka Capital Management Inc. owned about 0.10% of BeyondSpring at the end of the most recent quarter. 1.22% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This article was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/3079557/hc-wainwright-reiterates-60-00-price-target-for-beyondspring-bysi.html.
BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).
Receive News & Ratings for BeyondSpring Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring Inc. and related companies with MarketBeat.com's FREE daily email newsletter.